An extensive study of the hypotensive properties of protoveratrine, a pure crystalline ester alkaloid from Veratrum album, has been made in hypertensive and normotensive individuals. This drug is shown to be capable of lowering the blood pressure in hypertension of varied etiologies including essential hypertension, acute or chronic renal disease, malignant hypertension, toxemia of pregnancy, and carcinoma of the adrenal cortex. The relationships between dose and response from single intravenous, continuous intravenous, intramuscular and oral administration have been determined.
IT WAS SHOWN in a previous communication' that protoveratrine has a hypotensive and cardiodecelerator effect in human hypertension. Although the alkaloid possesses a narrow therapeutic range it may find some application in the therapy of hypertensive disorders. The practical usefulness of a drug, as a tool in the study of human physiology, or as a therapeutic agent, depends upon accurate knowledge of the relation between dose and response. As a rule, this relation varies with the route of administration. Hence, the studies reported earlier were extended to yield information on the influence of the route of administration upon the effect of protoveratrine on blood pressure and heart rate.
METHOD
Ten normal persons as well as 83 patients with hypertension of various origins were used for this study. The administration of protoveratrine was by single intravenous injections (284 injections in 71 patients and three normal subjects); by continuous intravenous infusion (46 infusion experiments in 20 hypertensive patients and seven normal individuals); by intramuscular injections (over 350 injections in 32 patients) and by the oral route (2 to over 800 doses in 15 patients). Most patients were ambulatory, coming into the hospital only for the duration of the study.
The protoveratrine used in these studies was pure crystalline material.* The infrared absorption spectrum of both samples was identical with that of the protoveratrine prepared by W. A. Jacobs which was used in the earlier studies. Melting point and rotation of the three samples did not differ significantly. Likewise the hypotensive responses obtained with the three samples of protoveratrine were indistinguishable.
For the intravenous administration single injections of a solution of 1:10,000 were used, while continuous infusions were made with dilute solutions of protoveratrine (0.5 to 1.5 jg. per cc. of 0.9 per cent sodium chloride solution or 5 per cent glucose solution) at desired rates. Most of the infusions were carried out for four to six hours; two lasted eight hours and one 96 hours. In 17 experiments the blood pressure was lowered by a single suitable intravenous injection. In 29 experiments the blood pressure fall was induced in a more gradual fashion (20 minutes to two hours) by administration of protoveratrine at rates of 1.8 to 7 jg. per minute, following which the blood pressure was maintained at a steady low level by the continuous infusion of very small amounts of protoveratrine (0.6 to 2.0 jig. per minute).
For the intramuscular injections solutions of 1:2000 were used. In order to prevent pain at the site of intramuscular injection, 1.0 to 2.0 per cent procaine hydrochloride was usually added. A 1 cc. graduated syringe and a number 25, 3 inch needle were used for these injections.
Solutions of 1:1000, compressed tablets, or timedisintegrating tabletst were used for oral medication.
The dose per tablet was 0.1 mg. or 0.5 mg.; the t Patient 26, L.P., a normotensive, is listed for comparison. t B.P. and H.R. before are the lowest levels of blood pressure and heart rate recorded during the control period preceding injection. B.P. and H.R. after are the lowest blood pressure and heart rate recorded for at least two readings following the injection. tablets were scored so as to facilitate adjustment of dosage.
Blood pressure measurements were made with a mercury sphygmomanometer in the usual manner and unless otherwise indicated denote the pressure in recumbency, except that blood pressure measurements in the studies with oral medication were in the sitting position. In most instances readings were made by the same two observers. Patients whose blood pressure could be influenced by placebo or who obtained marked reduction on bed rest were excluded from this study. Some of the patients who received oral protoveratrine had blood pressure readings taken at home, either by the patient or by a carefully instructed member of the family, as described by Ayman and Goldshine.2 Control studies have included administration of placebo and inadequiate doses of protoveratrine.
INTRAVENOUS ADMINISTRATION
As was pointed out earlier,' when protoveratrine is given intravenously to an individual patient the response is not only repeatable but predictable. Moreover, in a given patient within a certain dosage range, increasing the dose increased the fall in both systolic and diastolic pressure (B.Cr., J.F., S.M., B.M., M.R. in table 1). The relation between the increase in dose and increase in duration of action is less clear, although in general, larger doses caused greater duration of action. The response in the individual patient is so constant that a patient with known reaction to the drug can be used to assess the strength of an unknown protoveratrine solution. However, the variation from patient to patient in the response to a given dose is quite marked. It can be seen from table 1, which gives data on the response to intravenous protoveratrine of a group of patients with hypertension of different etiologies, that a very good hypotensive response (that is, a fall of blood pressure to or near the normal range) follows doses of the order of 1.6 to 1.9 jig. per kilogram of body weight in most of the patients listed. Figure 1 , which gives data on 51 patients (including the adult hypertensives in table 1), illustrates that a fall of blood pressure to or below 150 mm. Hg systolic and/or below 90 diastolic occurred in two-thirds of the patients with intravenous doses of 1.5 to 1.9 ,gg. per kilogram. However, some patients required considerably larger amounts. Only a few patients responded to doses less than 1.5 jig. per kilogram. This variation in dosage is apparently not related to the duration of the hypertension or its etiology (table 1). In the previous report' the dosage range studied was 0.08 to 0.20 mg. The highest dose given since then is 0.22 mg. Two patients have received 0.20 mg. in a single intravenous injection with a good vasodepressor response and no disturbance of cardiac rhythm or nausea. However, doses of this magnitude would cause nausea, vomiting, profound hypotension or disturbances in cardiac rhythm in most patients.
In view of the variation in dosage the evaluation of the vasodepressor properties of protoveratrine in a given patient requires the exploration of a range of increasing doses. The determination of a suitable intravenous dose should follow one of these plans: (A) An initial dose of 0.10 mg. of protoveratrine is given intravenously, slowly over two minutes. In a patient who is small, or well-digitalized, even less, 0.08 to 0.09 mg., might be used for the first trial. If no hypotensive risponse follows, the next dose given three to four hours later may be increased by 0.02 mg. until suitable effects are obtained. Once a dose of moderate hypotensive action is found, increments of only 0.01 mg. will cause measurably greater vasodepressor action. (B) If it is desired to obtain a prompt response, the initial dose of 0.10 mg. may be followed by 0.02 mg. at 10-minute in- tervals until a suitable low level is reached ( fig. 2 ). Injections must be at least 10 minutes apart since this is the time required to obtain the maximum effect from the preceding dose and measurements of blood pressure and heart rate should be made every two minutes during this period. Duration of action of a single effective intravenous injection is one to three hours,' occasionally longer. Durations greater than three hours are difficult to evaluate since in some instances control blood pressure levels may not be regained for as long as 12 hours. However, repetition of the same dose within two hours
will cause a significantly greater hypotensive response.
Toxicity. The range between an effective and a toxic dose is relatively narrow. A patient who responds to 0.1 mg. with a good hypotensive reaction free of side effects, may have nausea, epigastric and substernal discomfort, marked hypotension, bradyeardia or even arrhythmias after 0.13 mg. The administration of atropine, 0.5 to 0.8 mg. intravenously or 1 mg. sub-
3. E.P., a 45 year old woman with chronic glomerulonephritis and hypertension. At A, 0.11 mg. of protoveratrine was injected intravenously; at BY 0.4 mg. atropine sulfate intravenously. There was a prompt rise in blood pressure to control values coincident with the acceleration of heart rate, but the blood pressure soon fell although the bradycardia was not restored. The same phenomenon is illustrated in an exaggerated form on the right. At C, 0.16 mg. protoveratrine was given intravenously and at D, 0.8 mg. atropine sulfate subcutaneously. It is quite obvious that the hypotensive effect returned despite an increase in heart rate. cutaneously, will prevent or abolish the bradycardia or arrhythmia, but is without effect on the nausea or substernal discomfort. With proper attention to dosage, vomiting need not occur after single intravenous administration. We have had no instances of vomiting in a series of 284 injections. Nausea or substernal discomfort appeared 18 times.
Marked bradyeardia, as well as nausea, is more likely in patients who are digitalized. A woman aged 64, weighing 51 Kg., who had been taking 0.2 mg. digitoxin daily, developed bradyeardia with numerous extrasystoles after only 0.08 mg. of protoveratrine intravenously. Injection of 0.8 mg. atropine sulfate intravenously stopped the bradyeardia and extrasystoles. However, despite a spontaneous bradyeardia or .digitalization one may occasionally obtain a good hypotensive response from protoveratrine without further slowing of the heart rate.
In seven patients, of the 71 studied, a limiting factor in obtaining a good hypotensive response was the appearance of marked slowting of the heart, out of proportion to the fall in blood pressure, with nodal rhythm (one patient) or ventricular extrasystoles (one patient). Three of the seven patients were on maintenance doses of digitoxin.
Severe hypotensive effect is best counteracted by ephedrine sulfate, 25 mg. or more subcutaneously. Epinephrine is also effective. The patient should be kept flat and not allowed to walk about during a severe hypotensive reaction (for example, under 90 mm. Hg systolic). It is not unusual to see a blood pressure fall to as low as 90/50 without any subjective discomfort to the patient other than a sense of lightheadedness.
Atropine usually exerts only slight moderating effects on the hypotensive response,' but occasionally it may cause a temporary rise in blood pressure to control levels or higher ( fig.  3 ). However, after the tachycardia has subsided and the heart rate regained control values, the blood pressure falls distinctly below its control level. This emphasizes again that the hypotensive effect of protoveratrine is not dependent on the presence of bradyeardia, although greater vasodepressor action is observed at slow heart rates. This type of response to atropine ( fig. 3 ) is similar to that reported by Assali and co-workers when tetraethylammonium chloride is given during the maximum action of Veratrone.3 They suggested that it indicated a blocking effect of tetraethylammonium chloride on the neurogenic mechanism responsible for the hypotension. The occurrence of a similar response after atropine, however, suggests that this transient rise in blood pressure may not necessarily be due to the ganglionic blocking action. It may be the result of the tachycardia (and rise in cardiac output) which follows both tetraethylammonium chloride and atropine.
CONTINUOUS INTRAVENOUS INFUSION
Since protoveratrine is eliminated slowly and since its effects are probably a function of the concentration of the drug at the sites of action, continuous intravenous infusions were given to see (1) at what rate elimination proceeds in the human organism, (2) whether maintaining the concentration of the drug at a constant level would result in steady levels of blood pressure and (3) whether graded hypotensive responses could be obtained by varying the rate of infusion.
Three typical experiments on one patient, a woman with malignant hypertension, are shown in figure 4. A control experiment with 1 MAg.
per minute for over four hours was without effect; 2 MAg. per minute lowered the blood pressure to normal in two hours and 3 ,ug. per minute in one hour. Thereafter, 1.1 gg. per minute sufficed to maintain the blood pressure at an essentially steady level as long as the infusion was continued.
Since the rate of infusion of drug capable of maintaining a steady blood pressure level must equal the amount which is eliminated by the body, it was possible to determine this value from such experiments. The values found ranged from 0.6 to 2.0 ,ug. per minute. For 15 of 20 hypertensive patients it appeared to be of the order of 1 pg. per minute.
If the size of the initial hypotensive dose is known (see fig. 1 ), as well as the rate of infusion necessary to maintain a steady low blood pressure level, it is possible to calculate the approximate time necessary to lower the blood pressure to normal with any desired rate of infusion of protoveratrine. As the rate of administration of the protoveratrine solution is increased, the time required to induce a good hypotensive effect decreases. At 2 ,g. per minute the time required to lower the blood pressure to "normal" (120-130/80-90 mm. Hg) varied from 70 to 114 minutes (four patients); at 3 pg. per minute, the time was 37 to 70 minutes (five patients); at 4 ;Ag. per minute, 24 to 43 minutes (six patients).
When the rate of administration is very rapid, the response becomes similar to that of a single intravenous injection. For example, one patient (E.P., table 1) received 60 Mg.
per minute for two minutes, followed by 0.75 pg. per minute for four hours. There was a rapid hypotensive effect reaching a maximum in seven minutes, after which the blood pressure was maintained at an essentially constant and normal level throughout the duration of the infusion. When the infusion was discontinued the blood pressure rose slowly during the next four to five hours to control levels. During the continuous infusion side effects were absent. In fact, the patient's symptoms of hypertensive encephalopathy (headache and nausea) were strikingly alleviated. Although nausea may appear as a result of excessive amounts of the drug, in this instance nausea, present continuously for a week, disappeared with the fall in blood pressure and the patient was able to eat during the infusion with no discomfort. At the same time her headache became much less severe. When the blood pressure rose again her headache returned in its original intensity; the nausea recurred but in lessened degree. Close attention is necessary during infusion at rapid rates since it would require only a short time to introduce a dose considerably in excess of that required for optimal hypotension free of side effects. Since the maximum effect of the drug does not appear for about 10 minutes, an excessive dose might easily be given during this time, resulting in nausea, vomiting and probably profound hypotension. For example, at 5 gg. per minute, 10 additional minutes of infusion would probably raise the total administered dose to toxic levels. As a rule the infusion should be reduced to 1 Mg. per minute after administration of a dose equal to the priming dose (see fig. 1 ), plus 1 gg. for every minute of the infusion. At slower rates of infusion, such as 2 to 4 Mg. per minute, a satisfactory response will be obtained if the rate of the infusion is decreased to 1 jig. per minute when the systolic level has fallen to 140 to 150 mm. Hg. A steady state at about 120 to 130 mm. Hg systolic will be reached during the following 10 to 15 minutes.
Administration of protoveratrine to normotensive individuals at rates which would cause significant blood pressure lowering in hypertensives may cause no change in blood pressure or a modest fall. A normal woman who received 100 Mg. intravenously, followed, after a five-minute delay because of slight nausea, by 1 The intravenous administration of protoyeratrine-by continuous infusion thus makes it possible to lower the blood pressure to desired levels in a controlled fashion. Although such technics may have limited clinical application, they are of importance in physiologic studies in which the maintenance of a steady lowered blood pressure level is necessary to compare data in the hypertensive state with data at normotensive levels.
INTRAMUSCULAR ADMINISTRATION
Prolonged vasodepressor action as well as greater ease of administration is afforded by intramuscular injections of protoveratrine. As would be expected, the vasodepressor action after intramuscular injection is not as quantitatively reproducible in the same patient as after intravenous administration, probably due to variations in absorption. The effective intramuscular dose was found to be twvo and one-half to three and one-half times the effective single intravenous dose. To establish the intramuscular dose in a previously untested patient we begin with an initial dose of 0.30 mg. If this is completely ineffective, subsequent doses, at intervals of eight hours, are increased by 0.05 mg. If a dose is reached which causes a moderate hypotensive effect, the next dose is increased by only 0.03 mg. The largest single intramuscular dose we have used was 0.6 mg. in a patient who tolerated 0.2 mg. intravenously (A.N., table 1) . The dose of 0.6 mg. is unusually large and it caused nausea in this case, but even smaller doses (0.45 to 0.50 gm.) may cause vomiting in susceptible individuals. In adults, on the basis of body weight, the average intramuscular dose in over 32 adult patients was 4 to 6 Mg. per kilogram. Studies on a small group of four children indicate that 3 to 5 Mg. per kilogram appears to be a suitable intramuscular dose.
Noticeable blood pressure decreases after intramuscular injections do not appear earlier than 20 minutes following injection. A maximum effect is reached in 30 to 60 minutes. A good hypotensive response usually persists for four to six hours, occasionally as long as 12 hours. It is not possible to increase the duration of action further by increasing the size of the dose. Cumulative action usually occurs if the drug is administered ili the same dose at in-tervals of less than eight hours. Repeated administration at 8 to 12 hour intervals can be carried out. Figure 5 illustrates the blood pressure variations during five days of intramuscular administration to a patient with essential hypertension. On the last day, a slight increase in dosage caused a marked hypotension. Nausea and vomiting did not occur. However, when her blood pressure fell to 80/40 she felt very faint in the erect position and had to remain recumbent until her pressure rose to 100 to 110 mm. Hg systolic. The drug has been given intramuscularly repeatedly, usually at intervals of eight hours, for periods of a few days to six weeks. One patient received 90 consecutive intramuscular injections at 8 or 12 hour intervals over 42 days without change in the effectiveness of the drug. Two patients have shown less effect to the same dose of the drug, one after seven and one after 10 days, but a good hypotensive effect could be secured by a larger dose, although the incidence of nausea and vomiting became greater. Both of these patients were receiving digitalis, and the change in their responsiveness might have been related to the action of digitalis.
The warmth, which is such a characteristic part of the immediate subjective response to intravenous injection, is of only minor degree after intramuscular medication. Nausea and vomiting, when they occur after excessive doses, are apt to be quite severe and may last-for 30 minutes.
ORAL AD-MINISTRATION Protoveratrine exerts its hypotensive as well as its toxic effects when given orally.
Studies have been made in a small group of 15 patients all of whom responded suitably to intravenous administration of protoveratrinie.-Eleven of them had essential hypertension (one in a malignant phase) and four had chronic nephritis and hypertension (two in the malignant phase). In this group, initial studies were made in the hospital with observations of blood pressure and pulse rate every half to one hour during the day. Three patients now take the drug on an outpatient status with blood pressure readings at home,' usually four times daily, with four readings at five-minute intervals each time. Blood pressure measurements are made by the patient or a member of the family.
In 5 of 15 patients (including one with malignant hypertension) no significant reduction of blood pressure could be obtained, even with doses that caused nausea, weakness or extreme bradyeardia. In six of the patients moderate but inconstant and probably insignificant reductions of blood pressure were obtained. In four of the patients, significant* reduction of blood pressure during part of the day could be obtained for long periods (three to seven months) with occasional episodes of nausea and vomiting. One patient of this group of four suffered a severe hypotensive reaction with fall in blood pressure from 220 120 to 80/40, but recovered uneventfully without treatment.
The daily dose ranged from 1.0 to 2.3 mg. in three to five divided doses, preferably taken after meals and at bedtime, at intervals of four to six hours.
On the basis of this small group of patients, it has not been possible to establish anly relation between the initravenous and the oral dose. The proper dosage is arrived at by trial, starting with 0.5 mg. at 9 a.m., and(l 0.25 mg. at * The differences between the average systolic and diastolic blood pressures during drug and control (placebo) periods are greater than twice the standard error of the difference between the two means, 219: 3 p.m. and 9 p.m. The size of the last two doses is raised in turn to 0.5 mg. and then the interval between doses is shortened and a fourth or even fifth dose added until an effect appears.
A portion of the record of home blood pressure readings of one of the favorable group of four patients is shown in figure 6 . This patient is a 62 year old active stockbroker. Each dot represents the average of four readings taken by his son. The abrupt rise on substitution of placebo and fall on resumption of protovera- FIG. 6. J.S., a 62 year old man with essential hypertension. Each dot represents the average of four readings, systolic and diastolic, taken by his son. Measurements were made three or four times daily. Neither the patient nor his son knew when placebo medication was substituted for protoveratrine. The solid black areas represent the time during which placebo was given. This chart represents the last two and one-half months of a study lasting over six months, which contained a similar placebo period earlier.
trine is notable and has been repeated several times. In this patient, initial control readings were 190-220 systolic and 110-130 diastolic. During administration of protoveratrine most of the systolic readings fell below 190 and most of the diastolic readings below 110. During placebo periods the readings were usually above 190 systolic and 110 diastolic.
In figure 7 is shown the actual blood pressure readings on three typical days during a sevenmonth period of study of another patient, a 42 year old housewife who had a bilateral thoracolumbar sympathectomy one and onehalf years before for malignant hypertension. Her papilledema cleared but her blood pressure measurements remained unchanged. She received protoveratrine orally for seven months without evidence of tolerance. She was able to carry on all household duties including care of a young child during this time. The first day shown in figure 7 is the last day of a placebo period, the next two are on resumption of protoveratrine. When the drug is administered orally, one may see considerable variation in blood pressure readings during a single day and from one day to the next. It is quite obvious from figure 7 that the result depends on what time of day the blood pressure determination was made. Moreover, a larger oral dose (as on the third day) does not necessarily give MAR. 20 MML.2I FIG. 7. M.B ., a 42 year old woman. This represents three typical days out of a seven-month period on oral protoveratrine. Blood pressure measurements were taken by the patient. March 19 is the last day of a two-week placebo period and March 20 and 21, the first two on resumption of protoveratrine. The patient voluntarily took one-half the dose at 8 p.m. on March 20 because she noted how low her blood pressure was. a greater hypotensive response. It is also apparent that blood pressure control is achieved during only part of the day.
A patient who can cope with an occasional spell of nausea or vomiting or a rare severe hypotensive reaction may take the drug for long periods (six to seven months). Evaluation of benefit to be derived from such a program will require prolonged study. However, there is striking alleviation of subjective symptoms, such as headache, with reappearance of these symptoms on substitution of placebo therapy. SUMMARY The dose-response relations of protoveratrine in man have been studied in 83 hypertensive and 10 normal persons, with 284 intravenous injections, 46 continuous intravenous infusions, over 350 intramuscular injections and over 2000 oral doses.
A good hypotensive effect lasting one to three hours was usually obtained with intravenous doses of 1.5 to 1.9 pg. per kilogram.
In a given individual a suitable hypotensive effect could be obtained either by exploring a range of slowly increasing doses or by giving an initial dose of 0.1 mg., followed by 0.02 mg. at 10-minute intervals. A marked bradycardia, especially in digitalized patients, may prevent attainment of a satisfactory low blood pressure. Atropine and ephedrine, respectively, are effective agents against excessive bradycardia and hypotension duie to overdosage.
Administration of protoNveratrine by continuous intravenous infusion at rates of 2 to 7 jig. per minute make it possible to obtain graded hypotensive responses. The lowered level can be maintained at a steady state for many hours by infusions of the order of 1 pg. per minute.
Intramuscular injections, in doses of 4 to 6 pg. per kilogram, have been given at intervals of 8 to 12 hours for as long as six weeks with good hypotensive effects. Oral administration produced significant blood pressure lowering in only 4 of 15 patients who took the drug for three to seven months, without evidence of tolerance. There were occasional episodes of nausea and vomiting and there was one severe hypotensive reaction.
